PL37  (Synonyms: Debio-0827)

PL37 (Debio-0827) is an orally active Enkephalinase dual inhibitor (dual inhibition refers to the simultaneous inhibition of Neutral Endopeptidase and Aminopeptidase N activities). PL37 exerts its anti-hyperalgesic effects by activating μ-opioid receptors (µ-opioid receptors), with an ED₅₀ value of 13.4 mg/kg for analgesic effects in mice. PL37 can be used to study diabetic neuropathic pain^[1][2][3][4].

518.71

C₂₂H₃₄N₂O₆S₃

935481-06-4

CSCC[C@H](N)CSSC[C@@H](CC1=CC=CC=C1)C(NCC(OC(C)OC(OCC)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Menéndez L, et al. Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin. Eur J Pharmacol. 2008 Oct 31;596(1-3):50-5.  [Content Brief]

  [2]. Tesfaye S. PL37: a new hope in the treatment of painful diabetic neuropathy?[J]. Pain Management, 2016, 6(2): 129-132.  [Content Brief]

  [3]. González-Rodríguez S, et al. Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors. Neurosci Lett. 2009 Nov 20;465(3):285-9.  [Content Brief]

  [4]. Descheemaeker A, et al. Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model. Brain. 2022 Aug 27;145(8):2664-2670.  [Content Brief]